{
    "ticker": "FLXR",
    "name": "Flexion Therapeutics, Inc.",
    "description": "Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with musculoskeletal conditions. Founded in 2007 and headquartered in Burlington, Massachusetts, Flexion focuses on the discovery and development of proprietary therapies that address unmet medical needs in pain management and joint health. The company's lead product, Zilretta (triamcinolone acetonide extended-release injectable suspension), is an FDA-approved treatment for osteoarthritis pain in the knee. Zilretta offers patients prolonged pain relief through a novel delivery system that provides a sustained release of medication directly into the joint. Flexion is committed to advancing its pipeline of products, which includes additional formulations and therapies designed to improve outcomes for patients suffering from chronic pain. With a strong focus on patient-centric research and development, Flexion aims to enhance the quality of life for individuals affected by debilitating musculoskeletal disorders. The company continues to explore potential partnerships and collaborations to expand its reach and impact in the healthcare sector.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Burlington, Massachusetts, USA",
    "founded": "2007",
    "website": "https://www.flexiontherapeutics.com",
    "ceo": "Michael Clayman",
    "social_media": {
        "twitter": "https://twitter.com/FlexionThera",
        "linkedin": "https://www.linkedin.com/company/flexion-therapeutics"
    },
    "investor_relations": "https://investors.flexiontherapeutics.com",
    "key_executives": [
        {
            "name": "Michael Clayman",
            "position": "CEO"
        },
        {
            "name": "Rafael A. L. R. de Lima",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Zilretta"
            ]
        }
    ],
    "seo": {
        "meta_title": "Flexion Therapeutics, Inc. | Innovative Medicines for Pain Management",
        "meta_description": "Learn about Flexion Therapeutics, Inc., a biopharmaceutical company focused on developing innovative treatments for musculoskeletal conditions.",
        "keywords": [
            "Flexion Therapeutics",
            "Zilretta",
            "Musculoskeletal Disorders",
            "Pain Management",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Flexion Therapeutics known for?",
            "answer": "Flexion Therapeutics is known for its innovative medicines for musculoskeletal conditions, particularly its product Zilretta for osteoarthritis pain."
        },
        {
            "question": "Who is the CEO of Flexion Therapeutics?",
            "answer": "Michael Clayman is the CEO of Flexion Therapeutics, Inc."
        },
        {
            "question": "Where is Flexion Therapeutics headquartered?",
            "answer": "Flexion Therapeutics is headquartered in Burlington, Massachusetts, USA."
        },
        {
            "question": "What is Zilretta?",
            "answer": "Zilretta is an FDA-approved injectable suspension for the treatment of osteoarthritis pain in the knee."
        },
        {
            "question": "When was Flexion Therapeutics founded?",
            "answer": "Flexion Therapeutics was founded in 2007."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "ABBV",
        "AMGN"
    ],
    "related_stocks": [
        "MRNA",
        "GILD",
        "VRTX",
        "BMY"
    ]
}